IDP PHARMA

IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). They are currently focused on exploiting new mechanisms of action to treat cancer diseases. Multiple myeloma is one of their priorities. IDP Pharma's efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, the company has built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.